Q: No questions in the database.

Winner on COVID vaccine fight as they supply the material needed for test kits,. etc. Stock up a lot this year but seems to have started gaining traction with new CEO ~5 years ago - and started international growth.

Balance sheet in good shape and increasing ROE. Expensive.

What do you think longer term?